Available from: Dariush Mozaffarian 1, Monica Agarwal 2, Monica Aggarwal 3, Lydia Alexander 4, Caroline M Apovian 5, Shagun Bindlish 6, Jonathan Bonnet 7, W Scott Butsch 8, Sandra Christensen 9, Eugenia Gianos 10, Mahima Gulati 11, Alka Gupta 12 13, Debbie Horn 14, Ryan M Kane 15 16, Jasdeep Saluja 17, Deepa Sannidhi 18, Fatima Cody Stanford 19 20, Emily A Callahan 1
Liraglutide also reduced endothelial tight junction protein barriers, ameliorated ox-LDL induced endothelial monolayer permeability, and inhibited ox-LDL induced expression of vascular adhesion molecules (E-selectin and vascular cell adhesion molecule- 1), preventing ox-LDL induced monocyte adhesion to endothelial cells [57]
The combination of reduced oral intake from appetite suppression and fluid losses from gastrointestinal symptoms creates a vulnerable period, especially during the first 812 weeks of therapy or following dose increases
Lancet Diabetes Endocrinol 2021;9:825-36.ArticlePubMed 129
Many conditions such as high blood pressure, diabetes, high cholesterol, liver disorders, and even certain chest or bone abnormalities can develop quietly, often without noticeable symptoms
